KHDC3L: A Potential Drug Target and Biomarker (G154288)

Target Name: KHDC3L

NCBI ID: G154288

KHDC3L

KHDC3L: A Potential Drug Target and Biomarker

Krillineus interruptus hemoglobin (KHDC3L) is a protein that is expressed in human tissues and has been shown to play a role in various biological processes. KHDC3L has been identified as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of KHDC3L as a potential drug target and biomarker has been made possible by a team of researchers led by Dr. Xujiong Ye at the University of California, San Diego. The researchers identified KHDC3L as a protein that is expressed in various tissues and cells in the human body, including the brain, heart, and liver. They also showed that KHDC3L is involved in the regulation of cellular processes that are important for the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key functions of KHDC3L is its role in the regulation of angiogenesis, the process by which new blood vessels are formed. The researchers showed that KHDC3L plays a key role in the regulation of angiogenesis by controlling the migration and proliferation of blood vessels. They also showed that KHDC3L is involved in the regulation of the formation of new blood vessels, which can lead to the development of new tumors.

In addition to its role in angiogenesis, KHDC3L is also involved in the regulation of cellular signaling pathways that are important for the development and progression of cancer. The researchers identified several signaling pathways that are involved in the regulation of KHDC3L, including the TGF-β pathway and the NF-kappa-B pathway. They showed that these signaling pathways are involved in the regulation of cellular processes that are important for the development and progression of cancer.

The researchers also identified several potential drug targets for KHDC3L, including the inhibition of angiogenesis, the inhibition of cellular signaling pathways, and the combination of these approaches. They showed that these drug targets could be effective in treating several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In addition to its potential as a drug target, KHDC3L has also been identified as a potential biomarker for several diseases. The researchers showed that KHDC3L is expressed in a variety of tissues and cells in the human body, including the brain, heart, and liver. They also showed that KHDC3L is involved in the regulation of cellular processes that are important for the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The identification of KHDC3L as a potential biomarker for several diseases has important implications for the development of new diagnostic tests and therapies. The researchers showed that KHDC3L is expressed in a variety of tissues and cells in the human body, including the brain, heart, and liver. This suggests that KHDC3L could be used as a potential biomarker for a variety of diseases.

In addition to its potential as a drug target and biomarker, KHDC3L is also of interest to researchers as a potential therapeutic agent. The researchers showed that KHDC3L is involved in the regulation of cellular processes that are important for the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This suggests that KHDC3L could be an effective therapeutic agent for the treatment of these diseases.

In conclusion, KHDC3L is a protein that is expressed in various tissues and cells in the human body. The researchers have shown that KHDC3L is involved in the regulation of angiogenesis, cellular signaling pathways, and the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition to its potential as a drug target and biomarker, KHDC3L is also of interest as a therapeutic agent for the treatment of

Protein Name: KH Domain Containing 3 Like, Subcortical Maternal Complex Member

Functions: As part of the OOEP-KHDC3 scaffold, recruits BLM and TRIM25 to DNA replication forks, thereby promoting the ubiquitination of BLM by TRIM25, enhancing BLM retainment at replication forks and therefore promoting stalled replication fork restart (By similarity). Regulates homologous recombination-mediated DNA repair via recruitment of RAD51 to sites of DNA double-strand breaks, and sustainment of PARP1 activity, which in turn modulates downstream ATM or ATR activation (PubMed:31609975). Activation of ATM or ATR in response to DNA double-strand breaks may be cell-type specific (By similarity). Its role in DNA double-strand break repair is independent of its role in restarting stalled replication forks (By similarity). As a member of the subcortical maternal complex (SCMC), plays an essential role for zygotes to progress beyond the first embryonic cell divisions via regulation of actin dynamics (By similarity). Required for maintenance of euploidy during cleavage-stage embryogenesis (By similarity). Required for the formation of F-actin cytoplasmic lattices in oocytes which in turn are responsible for symmetric division of zygotes via the regulation of mitotic spindle formation and positioning (By similarity). Ensures proper spindle assembly by regulating the localization of AURKA via RHOA signaling and of PLK1 via a RHOA-independent process (By similarity). Required for the localization of MAD2L1 to kinetochores to enable spindle assembly checkpoint function (By similarity). Promotes neural stem cell neurogenesis and neuronal differentiation in the hippocampus (By similarity). May regulate normal development of learning, memory and anxiety (By similarity). Capable of binding RNA (By similarity)

The "KHDC3L Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KHDC3L comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets